| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2000;101:955.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Cardiac Catheterization Laboratory and Department of Medicine, Montreal Heart Institute, Montreal, Quebec, Canada.
Correspondence to Serge Doucet, MD, Research Centre, Montreal Heart Institute, 5000 Bélanger St E, Montreal, Quebec, Canada H1T 1C8.
BackgroundThe treatment of unstable angina targets the specific pathophysiological thrombotic process at the site of the active culprit lesion. In unstable angina due to a restenotic lesion, smooth muscle cell proliferation and increased vasoreactivity may play a more important role than thrombus formation. Therefore, the relative benefits of nitroglycerin and heparin might differ in unstable angina associated with restenosis compared with classic unstable angina.
Methods and ResultsWe randomized 200 patients hospitalized for unstable angina within 6 months after angioplasty (excluding those with intracoronary stents) to double-blind administration of intravenous nitroglycerin, heparin, their combination, or placebo for 63±30 hours. Recurrent angina occurred in 75% of patients in the placebo and heparin-alone groups, compared with 42.6% of patients in the nitroglycerin-alone group and 41.7% of patients in the nitroglycerin-plus-heparin group (P<0.003). Refractory angina requiring angiography occurred in 22.9%, 29.2%, 4.3%, and 4.2% of patients, respectively (P<0.002). The odds ratios for being event free were 0.24 (95% CI, -0.13 to 0.45, P=0.0001) for nitroglycerin versus no nitroglycerin and 0.98 (95% CI, -0.55 to 1.73, P=NS) for heparin versus no heparin. No patient died or suffered myocardial infarction.
ConclusionsIntravenous nitroglycerin is highly effective in preventing adverse ischemic events (recurrent or refractory angina) in patients with unstable angina secondary to restenosis, whereas heparin has no effect.
Key Words: angina restenosis nitroglycerin heparin ischemia
This article has been cited by other articles:
![]() |
P. A. Lemos, P. W. Serruys, and J. E. Sousa Drug-Eluting Stents: Cost Versus Clinical Benefit Circulation, June 24, 2003; 107(24): 3003 - 3007. [Full Text] [PDF] |
||||
![]() |
B. Chandrasekar, S. Nattel, and J.-F. Tanguay Coronary artery endothelial protection after local delivery of 17{beta}-estradiol during balloon angioplasty in a porcine model: a potential new pharmacologic approach to improve endothelial function J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1570 - 1576. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association Arterioscler. Thromb. Vasc. Biol., July 1, 2001; 21 (7): e9 - e9. [Full Text] [PDF] |
||||
![]() |
J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association Circulation, June 19, 2001; 103(24): 2994 - 3018. [Full Text] [PDF] |
||||
![]() |
Nitroglycerin for Unstable Angina Due to Restenosis Journal Watch Cardiology, March 31, 2000; 2000(331): 7 - 7. [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |